Edition:
India

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

93.16USD
8:44pm IST
Change (% chg)

$-0.51 (-0.54%)
Prev Close
$93.67
Open
$93.69
Day's High
$93.88
Day's Low
$93.03
Volume
422,607
Avg. Vol
3,000,473
52-wk High
$95.42
52-wk Low
$58.61

Latest Key Developments (Source: Significant Developments)

Celgene Stockholders Approve Proposed Acquisition By Bristol-Myers Squibb
Friday, 12 Apr 2019 

April 12 (Reuters) - Celgene Corp ::CELGENE STOCKHOLDERS APPROVE PROPOSED ACQUISITION BY BRISTOL-MYERS SQUIBB.CELGENE CORP - CELGENE EXPECTS TRANSACTION TO CLOSE IN Q3 OF 2019.CELGENE CORP - APPROXIMATELY 98% OF VOTES CAST, AND OVER 70% OF SHARES OUTSTANDING AND ENTITLED TO VOTE, VOTED IN FAVOR OF TRANSACTION.  Full Article

Dr.Reddy's Laboratories Enter Settlement Agreement With Celgene
Tuesday, 2 Apr 2019 

April 2 (Reuters) - Celgene Corp ::DR.REDDY'S LABORATORIES- ENTERED SETTLEMENT AGREEMENT WITH CELGENE FOR ANDS RELATED TO GENERIC VERSION OF REVLIMID® BRAND CAPSULES.DR.REDDY'S LABORATORIES-CO, CELGENE AGREED TO DISCONTINUE LEGAL PROCEEDINGS INVOLVING CERTAIN OF CELGENE'S CANADIAN PATENTS RELATED TO LENALIDOMIDE.  Full Article

Bristol-Myers Says It Is Pleased Celgene Reached Settlement With Alvogen On Revlimid Patent Litigation
Friday, 29 Mar 2019 

March 29 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB ISSUES STATEMENT ON CELGENE’S SETTLEMENT WITH ALVOGEN ON REVLIMID® PATENT LITIGATION.BRISTOL-MYERS SQUIBB CO - CONFIDENT IN STRENGTH OF OUR COMBINATION WITH CELGENE.BRISTOL-MYERS SQUIBB CO - CO, CELGENE EXPECT TRANSACTION TO CLOSE IN Q3.BRISTOL-MYERS SQUIBB CO - PLEASED THAT CELGENE HAS REACHED A SETTLEMENT WITH ALVOGEN RELATED TO PATENTS FOR REVLIMID.  Full Article

Starboard To Withdraw Proxy Solicitation to Vote Against Bristol-Myers & Celgene Deal
Friday, 29 Mar 2019 

March 29 (Reuters) - Starboard Value LP::STARBOARD ISSUES STATEMENT ON BRISTOL-MYERS.HAS DECIDED TO WITHDRAW ITS PROXY SOLICITATION TO VOTE AGAINST CELGENE TRANSACTION."CONTINUE TO FEEL STRONGLY THAT PROPOSED TRANSACTION BETWEEN BRISTOL-MYERS AND CELGENE CORPORATION IS A BAD DEAL FOR SHAREHOLDERS".CONTINUE TO INTEND TO VOTE SHARES AGAINST BRISTOL-MYERS AND CELGENE DEAL AT UPCOMING SPECIAL MEETING.  Full Article

Celgene Settles U.S. REVLIMID Patent Litigation With Alvogen
Friday, 29 Mar 2019 

March 29 (Reuters) - Celgene Corp ::CELGENE SETTLES U.S. REVLIMID® PATENT LITIGATION WITH ALVOGEN.EARLIEST LICENSED ENTRY OF ANY GENERIC LENALIDOMIDE IN U.S. CONTINUES TO BE MARCH 2022, BASED ON SETTLEMENTS REACHED.ALVOGEN ALSO LICENSED TO SELL GENERIC LENALIDOMIDE IN U.S. WITHOUT VOLUME LIMITATION BEGINNING ON JANUARY 31, 2026.ALVOGEN LICENSED TO SELL GENERIC LENALIDOMIDE IN U.S. BEGINNING ON A CONFIDENTIAL DATE AFTER MARCH 2022 DATE CO PREVIOUSLY GAVE TO NATCO.CO, LOTUS PHARMACEUTICAL CO LTD AND ALVOGEN PINE BROOK LLC ANNOUNCED SETTLEMENT OF THEIR LITIGATION RELATING TO PATENTS FOR REVLIMID.  Full Article

Celgene Receives CHMP Positive Opinions For Both Revlimid & Imnovid-Based Triplet Combination Regimens For Patients With Multiple Myeloma
Friday, 29 Mar 2019 

March 29 (Reuters) - Celgene Corp ::CELGENE RECEIVES CHMP POSITIVE OPINIONS FOR BOTH REVLIMID® (LENALIDOMIDE) AND IMNOVID® (POMALIDOMIDE)-BASED TRIPLET COMBINATION REGIMENS FOR PATIENTS WITH MULTIPLE MYELOMA.CELGENE CORP - CHMP RECOMMENDED APPROVAL OF AN EXPANDED INDICATION OF REVLIMID AS COMBINATION THERAPY WITH BORTEZOMIB AND DEXAMETHASONE.CELGENE CORP - EUROPEAN COMMISSION IS EXPECTED TO MAKE ITS FINAL DECISION IN APPROXIMATELY TWO MONTHS..CELGENE CORP - CHMP ALSO RECOMMENDED APPROVAL OF IMNOVID IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE.  Full Article

Starboard Opposes Bristol-Myers' Proposed Acquisition Of Celgene
Tuesday, 19 Mar 2019 

March 19 (Reuters) - Bristol-Myers Squibb Co ::STARBOARD ISSUES INVESTOR PRESENTATION OPPOSING BRISTOL-MYERS SQUIBB'S ILL-ADVISED PROPOSED ACQUISITION OF CELGENE.STARBOARD ISSUES INVESTOR PRESENTATION OPPOSING BRISTOL-MYERS SQUIBB'S ILL-ADVISED PROPOSED ACQUISITION OF CELGENE.STARBOARD VALUE SAYS BELIEVES PROPOSED MERGER WITH CELGENE IS NOT IN BEST INTERESTS OF BRISTOL-MYERS SHAREHOLDERS.STARBOARD VALUE SAYS URGES ALL BRISTOL-MYERS SHAREHOLDERS TO REJECT PROPOSED CELGENE TRANSACTION.STARBOARD VALUE SAYS MAILED DEFINITIVE PROXY MATERIALS AND A BLUE PROXY CARD IN CONNECTION WITH BRISTOL-MYERS SQUIBB SPECIAL MEETING OF SHAREHOLDERS.  Full Article

Celgene Provides Update On Abraxane Combination Therapy
Wednesday, 13 Mar 2019 

March 12 (Reuters) - Celgene Corp ::CELGENE PROVIDES UPDATE ON ABRAXANE® COMBINATION THERAPY IN THE TREATMENT OF METASTATIC TRIPLE-NEGATIVE BREAST CANCER AND PANCREATIC CANCER.CELGENE CORP - TECENTRIQ WITH ABRAXANE RECEIVES ACCELERATED APPROVAL FOR PEOPLE WITH PD-L1-POSITIVE, METASTATIC TRIPLE-NEGATIVE BREAST CANCER.CELGENE - PHASE 3 APACT STUDY DID NOT ACHIEVE PRIMARY ENDPOINT.CELGENE CORP - SAFETY PROFILE OBSERVED IN APACT STUDY WAS CONSISTENT WITH PREVIOUSLY REPORTED STUDIES OF ABRAXANE.CELGENE - OVERALL SURVIVAL, A SECONDARY ENDPOINT OF PHASE 3 APACT STUDY, WAS IMPROVED, REACHING NOMINAL STATISTICAL SIGNIFICANCE.  Full Article

U.S. FDA Grants Priority Review For Fedratinib New Drug Application In Myelofibrosis
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Celgene Corp ::U.S. FDA GRANTS PRIORITY REVIEW FOR FEDRATINIB NEW DRUG APPLICATION IN MYELOFIBROSIS.CELGENE CORP - U.S. FOOD & DRUG ADMINISTRATION SETS PRESCRIPTION DRUG USER FEE ACT ACTION DATE FOR SEPT. 3, 2019.CELGENE CORP - PRESCRIPTION DRUG USER FEE ACT ACTION DATE FOR SEPT. 3, 2019.CELGENE CORP - CELGENE ALSO PLANS TO EVALUATE FEDRATINIB IN COMBINATION WITH LUSPATERCEPT.  Full Article

Celgene Corp - CEO Mark Alles' 2018 Total Compensation $16.2 Million Versus $13.1 Million In 2017 - SEC Filing
Saturday, 2 Mar 2019 

March 1 (Reuters) - Celgene Corp ::CELGENE CORP - CEO MARK ALLES' 2018 TOTAL COMPENSATION $16.2 MILLION VERSUS $13.1 MILLION IN 2017 - SEC FILING.CELGENE CORP - CFO DAVID ELKINS' 2018 TOTAL COMPENSATION WAS $13.1 MILLION.  Full Article

Deals of the day-Mergers and acquisitions

April 12 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday: